Hesse C, Bogdanovic N, Davidsson P, Blennow K
Department of Clinical Neuroscience, Unit of Neurochemistry, University of Göteborg, Sahlgren's University Hospital, Mölndal, Sweden.
Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):452-9. doi: 10.1159/000017189.
Apoliprotein E (ApoE) has been implicated in the pathogenesis of Alzheimer's disease (AD). Antibodies to ApoE label senile plaques (SP), and an interaction between ApoE and beta-amyloid has been found in in vitro studies. Further, an increased frequency of the ApoE epsilon4 allele in AD has been reported in numerous papers. However, the pathogenetic mechanism of ApoE in AD is not known. We studied ApoE in brain tissue (hippocampus, cerebellum, frontal and temporal cortex) from patients with AD and age-matched control subjects, using both quantitative Western blotting and immunohistochemistry. In AD, a reduction of ApoE was found in the hippocampus (50% of the control value) and in the frontal cortex (52% of the control value), while no significant changes in ApoE levels were found in the temporal cortex or in the cerebellum. Also by immunohistochemistry, ApoE staining was generally decreased in AD brains, both in the neuropil and in the neuronal cellular compartments. Within the AD group, there was no significant correlation between the ApoE level and SP or neurofibrillary tangle (NFT) counts, either in the hippocampus (r = -0.14 and r = 0.55, respectively), or in the frontal cortex (r = -0.03 and r = 0.01, respectively). There were no significant differences in duration, severity of dementia, SP or NFT counts, or ApoE levels between AD patients with different numbers of ApoE epsilon4 alleles. After experimental brain damage in animals, marked increases in ApoE are found, probably as part of lipid recycling in neuronal and synaptic remodelling and regeneration. One may speculate whether the decrease in ApoE may suggest a disturbance in the ApoE system in AD that is unrelated to ApoE isoforms, beta-amyloid deposition and NFT formation. Copyrightz1999S.KargerAG,Basel
载脂蛋白E(ApoE)与阿尔茨海默病(AD)的发病机制有关。针对ApoE的抗体可标记老年斑(SP),并且在体外研究中发现了ApoE与β-淀粉样蛋白之间的相互作用。此外,众多论文报道AD患者中ApoEε4等位基因的频率增加。然而,ApoE在AD中的发病机制尚不清楚。我们使用定量蛋白质免疫印迹法和免疫组织化学方法,研究了AD患者及年龄匹配的对照受试者脑组织(海马体、小脑、额叶和颞叶皮质)中的ApoE。在AD患者中,海马体(为对照值的50%)和额叶皮质(为对照值的52%)中的ApoE减少,而颞叶皮质或小脑中的ApoE水平未发现显著变化。同样通过免疫组织化学方法发现,AD患者脑内的ApoE染色在神经毡和神经元细胞区室中普遍减少。在AD组中,海马体(r分别为-0.14和0.55)或额叶皮质(r分别为-0.03和0.01)中ApoE水平与SP或神经原纤维缠结(NFT)计数之间均无显著相关性。携带不同数量ApoEε4等位基因的AD患者在病程、痴呆严重程度以及SP或NFT计数或ApoE水平方面均无显著差异。动物实验性脑损伤后,ApoE显著增加,这可能是神经元和突触重塑及再生过程中脂质循环的一部分。人们可能会推测,ApoE的减少是否表明AD中ApoE系统存在紊乱,这与ApoE异构体、β-淀粉样蛋白沉积和NFT形成无关。版权所有z1999S.KargerAG,巴塞尔